Mazor Robotics Ltd. (NASDAQ:MZOR) – Equities research analysts at First Analysis upped their Q3 2016 EPS estimates for shares of Mazor Robotics in a research report issued on Thursday. First Analysis analyst G. Chodaczek now anticipates that the brokerage will post earnings of ($0.16) per share for the quarter, up from their prior estimate of ($0.20). First Analysis also issued estimates for Mazor Robotics’ Q4 2016 earnings at ($0.06) EPS, FY2016 earnings at ($0.61) EPS, Q1 2017 earnings at ($0.12) EPS, Q2 2017 earnings at ($0.07) EPS and FY2017 earnings at ($0.25) EPS.

MZOR has been the subject of several other reports. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a report on Thursday, July 7th. Barclays PLC raised their price objective on shares of Mazor Robotics from $16.00 to $23.00 and gave the stock an “overweight” rating in a report on Thursday, July 14th. Standpoint Research began coverage on shares of Mazor Robotics in a report on Friday, July 8th. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Investment Research lowered shares of Mazor Robotics from a “hold” rating to a “sell” rating in a report on Friday. Finally, B. Riley began coverage on shares of Mazor Robotics in a report on Thursday, October 6th. They issued a “neutral” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. Mazor Robotics has an average rating of “Hold” and an average price target of $26.25.

Earnings History and Estimates for Mazor Robotics (NASDAQ:MZOR)

Mazor Robotics (NASDAQ:MZOR) opened at 23.75 on Monday. The stock’s market cap is $514.73 million. The stock has a 50 day moving average price of $23.40 and a 200-day moving average price of $18.37. Mazor Robotics has a 52 week low of $8.31 and a 52 week high of $26.55.

Mazor Robotics (NASDAQ:MZOR) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Mazor Robotics had a negative return on equity of 42.30% and a negative net margin of 60.75%. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $8.51 million. During the same quarter in the previous year, the business earned ($0.05) EPS. The company’s revenue was up 6.4% compared to the same quarter last year.

Several institutional investors have recently made changes to their positions in MZOR. Iguana Healthcare Management LLC increased its position in shares of Mazor Robotics by 60.0% in the second quarter. Iguana Healthcare Management LLC now owns 200,000 shares of the company’s stock worth $3,596,000 after buying an additional 75,000 shares in the last quarter. EAM Investors LLC acquired a new position in shares of Mazor Robotics during the second quarter worth $2,348,000. Candriam Luxembourg S.C.A. acquired a new position in shares of Mazor Robotics during the second quarter worth $1,079,000. Menta Capital LLC increased its position in shares of Mazor Robotics by 25.0% in the second quarter. Menta Capital LLC now owns 46,848 shares of the company’s stock worth $842,000 after buying an additional 9,366 shares in the last quarter. Finally, Trellus Management Company LLC increased its position in shares of Mazor Robotics by 11.6% in the second quarter. Trellus Management Company LLC now owns 23,982 shares of the company’s stock worth $431,000 after buying an additional 2,500 shares in the last quarter. 18.71% of the stock is owned by institutional investors and hedge funds.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

5 Day Chart for NASDAQ:MZOR

Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.